Status:

WITHDRAWN

Local Paclitaxel Delivery to Prevent Restenosis in Peripheral Arterial Disease

Lead Sponsor:

Jane Phillips Medical Center

Conditions:

Peripheral Arterial Disease

Restenosis

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to determine if the addition of a catheter-based local delivery of paclitaxel into the peripheral arterial vessels in patients with peripheral arterial disease (PAD) and s...

Detailed Description

Peripheral arterial disease (PAD) of the lower extremities is an extremely prevalent, and often times, disabling disorder reaching roughly 8 million people in the United States, and up to 20 percent o...

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Rutherford Stages 2-5 plus prior history of endovascular revascularization and recurrent stenosis (in stent, post angioplasty, post atherectomy) (Table 1 )
  • one or more restenotic lesions within the SFA of at least 70% of the vessel diameter
  • Successful percutaneous revascularization of the femoropopliteal artery (\< 20% residual stenosis by visual estimate) using standard techniques per discretion of the local operator
  • The femoropopliteal Reference Vessel Diameter (RVD) must be ≥4.0 mm and ≤7.0 mm

Exclusion

  • Patient is pregnant or breast feeding. (Female subjects of childbearing potential must have negative serum pregnancy test the day of the procedure.)
  • Life expectancy \< 12 months.
  • Contraindication to aspirin, clopidogrel or other thienopyridine, heparin, low molecular weight heparin, bivalirudin or other therapies required for procedure or follow up.
  • Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.
  • Known allergy to paclitaxel.
  • Uncontrolled hypercoagulability or history of HIT or HITTS syndrome.
  • Simultaneous enrollment in another investigational device or drug study.
  • Absence of at least 1 TIMI-3 vessel run off into the foot.
  • Platelet count \< 100,000/mm3.
  • White blood cell count \< 1.5/mm3.
  • Any evidence of perforation or dye extravasation during the index procedure, even if successfully treated with a covered stent.

Key Trial Info

Start Date :

August 1 2013

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 1 2013

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03858764

Start Date

August 1 2013

End Date

August 1 2013

Last Update

March 4 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.